Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineLiang Cheng, Rodolfo Montironi|Modern Pathology|2017Cited by 404
Immune Checkpoint Inhibitors for the Treatment of Bladder CancerAntonio López-Beltrán, Rodolfo Montironi, Alessia Cimadamore et al.|Cancers|2021Cited by 289
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsGaetano Aurilio, Rodolfo Montironi, Alessia Cimadamore et al.|Cells|2020Cited by 256
The World Health Organization 2016 classification of testicular non‐germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation PanelMuhammad T. Idrees, Thomas M. Ulbright, Esther Oliva et al.|Histopathology|2016Cited by 236
Frequent <i>FGFR3</i> mutations in urothelial papillomaBas W.G. van Rhijn, Theodorus van der Kwast, Rodolfo Montironi et al.|The Journal of Pathology|2002Cited by 189